Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations

  • Evgenii Shumilov
  • , Paolo Mazzeo
  • , Susanne Ghandili
  • , Axel Künstner
  • , Sören Weidemann
  • , Yara Banz
  • , Philipp Ströbel
  • , Matthias Pollak
  • , Lina Kolloch
  • , Helmut Beltraminelli
  • , Andrea Kerkhoff
  • , Jan Henrik Mikesch
  • , Christoph Schliemann
  • , Detlef Haase
  • , Gerald Wulf
  • , Myriam Legros
  • , Georg Lenz
  • , Laurence Feldmeyer
  • , Thomas Pabst
  • , Hanno Witte
  • Niklas Gebauer, Ulrike Bacher*
*Korrespondierende/r Autor/-in für diese Arbeit
  • Westfälische Wilhelms-Universität Münster
  • Georg-August-Universität Göttingen
  • Universitätsklinikum Hamburg-Eppendorf
  • University of Bern
  • Ente Ospedaliero Cantonale
  • Christian-Albrechts Universität zu Kiel
  • Federal Armed Forces Hospital

Abstract

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare malignancy derived from plasmacytoid dendritic cells, can mimic both acute leukemia and aggressive T-cell lymphoma. Therapy of this highly aggressive hematological disease should be initiated as soon as possible, especially in light of novel targeted therapies that have become available. However, differential diagnosis of BPDCN remains challenging. This retrospective study aimed to highlight the challenges to timely diagnoses of BPDCN. We documented the diagnostic and clinical features of 43 BPDCN patients diagnosed at five academic hospitals from 2001–2022. The frequency of BPDCN diagnosis compared to AML was 1:197 cases. The median interval from the first documented clinical manifestation to diagnosis of BPDCN was 3 months. Skin (65%) followed by bone marrow (51%) and blood (45%) involvement represented the most common sites. Immunophenotyping revealed CD4 +, CD45 +, CD56 +, CD123 +, HLA-DR +, and TCL-1 + as the most common surface markers. Overall, 86% (e.g. CD33) and 83% (e.g., CD7) showed co-expression of myeloid and T-cell markers, respectively. In the median, we detected five genomic alterations per case including mutational subtypes typically involved in AML: DNA methylation (70%), signal transduction (46%), splicing factors (38%), chromatin modification (32%), transcription factors (32%), and RAS pathway (30%), respectively. The contribution of patients (30%) proceeding to any form of upfront stem cell transplantation (SCT; autologous or allogeneic) was almost equal resulting in beneficial overall survival rates in those undergoing allogeneic SCT (p = 0.0001). BPDCN is a rare and challenging entity sharing various typical characteristics of other hematological diseases. Comprehensive diagnostics should be initiated timely to ensure appropriate treatment strategies.

OriginalspracheEnglisch
ZeitschriftAnnals of Hematology
Jahrgang103
Ausgabenummer5
Seiten (von - bis)1587-1599
Seitenumfang13
ISSN0939-5555
DOIs
PublikationsstatusVeröffentlicht - 05.2024

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

  • Profilbereich: Lübeck Integrated Oncology Network (LION)
  • Zentren: Universitäres Cancer Center Schleswig-Holstein (UCCSH)

DFG-Fachsystematik

  • 2.22-14 Hämatologie, Onkologie
  • 2.22-19 Dermatologie

Fingerprint

Untersuchen Sie die Forschungsthemen von „Diagnostic management of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in close interaction with therapeutic considerations“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren